Actinogen Medical Limited (AU:ACW) has released an update.
Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Actinogen Medical has launched a key phase 2b/3 trial for its Alzheimer’s treatment, Xanamem, with the first US participant now enrolled. This study aims to evaluate the drug’s impact on cognitive and functional measures in patients, with interim results expected in 2025 and final results in 2026. The trial, expanding across 25 sites in the US and Australia, showcases Actinogen’s dedication to advancing innovative treatments for neurological conditions.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
Actinogen Medical Expands Alzheimer’s Drug Trial to US
